SCHEMBL484886

SCHEMBL484886

CC(C)(C)OC(=O)N1CCC2(CCN(c3ccc(Cl)cc3)CC2)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B2 P19099 1/20 0.55
HTT P42858 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
GPR119 Q8TDV5 7/20 0.48
ALDH1A1 P00352 2/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
CYP3A4 P08684 5/20 0.46
CYP2C19 P33261 3/20 0.46
CYP2C9 P11712 2/20 0.46
CYP1A2 P05177 2/20 0.46
TSHR P16473 1/20 0.46
MAPK1 P28482 1/20 0.46
SCD5 Q86SK9 1/20 0.46
STS P08842 1/20 0.46
HDAC2 Q92769 1/20 0.45
USP2 O75604 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31342184 0.94 HTT (0.54) CYP11B2HTTSMN1; SMN2NPSR1MEN1
SCHEMBL1779228 0.92 SMN1; SMN2 (0.57) HTTSMN1; SMN2NPSR1MEN1KMT2A
SCHEMBL31276408 0.91 NPSR1 (0.51) CYP11B2HTTSMN1; SMN2NPSR1MEN1
SCHEMBL30769248 0.88 CYP11B2 (0.55) CYP11B2MEN1KMT2AGPR119ALDH1A1
SCHEMBL485607 0.88 HDAC2 (0.58) CYP11B2MEN1KMT2AGPR119ALDH1A1
SCHEMBL485392 0.86 CYP11B2 (0.54) CYP11B2SMN1; SMN2MEN1KMT2AGPR119
SCHEMBL485220 0.85 CYP11B2 (0.53) CYP11B2MEN1KMT2AGPR119ALDH1A1
SCHEMBL20842160 0.85 GPR119 (0.57) CYP11B2SMN1; SMN2MEN1KMT2AGPR119
SCHEMBL484102 0.85 HIF1A (0.63) CYP11B2SMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL484627 0.84 CYP11B2 (0.53) CYP11B2MEN1KMT2AGPR119ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130231327-A1 Substituted Spiro-Amide Compounds GRUENENTHAL GMBH (DE) 2013-09-05 US disclosed
US-8455475-B2 Substituted spiro-amide compounds GRUENENTHAL GMBH (DE) 2013-06-04 US disclosed
EP-2411381-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-02-01 EP disclosed
US-20100249095-A1 Substituted Spiro-amide Compounds GRUENENTHAL GMBH (DE) 2010-09-30 US disclosed
WO-2010108651-A1 SUBSTITUTED SPIRO-AMIDE COMPOUNDS Grünenthal GmbH (DE) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130231327-A1 Substituted Spiro-Amide Compounds BDKRB1, BDKRB2, REN CYP11B2 2150/4885HTT 3621/4885SMN1; SMN2 3545/4885
US-20100249095-A1 Substituted Spiro-amide Compounds BDKRB1, BDKRB2, REN CYP11B2 2150/4885HTT 3621/4885SMN1; SMN2 3545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.